Amyris (NASDAQ:AMRS) announced its earnings results on Monday. The biotechnology company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of $0.44 by ($1.51), Morningstar.com reports. The business had revenue of $19.36 million during the quarter, compared to the consensus estimate of $98.52 million. During the same quarter in the prior year, the business earned $0.61 EPS. The company’s revenue was down 76.0% on a year-over-year basis.
Shares of AMRS traded down $0.26 during mid-day trading on Tuesday, hitting $3.55. The company’s stock had a trading volume of 2,354,186 shares, compared to its average volume of 1,406,660. The stock has a market capitalization of $291.58 million, a P/E ratio of -1.16 and a beta of 0.39. Amyris has a 1-year low of $2.64 and a 1-year high of $9.28.
AMRS has been the topic of several analyst reports. BidaskClub downgraded Amyris from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. HC Wainwright set a $11.00 target price on Amyris and gave the company a “buy” rating in a research note on Tuesday, February 5th. Finally, Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Amyris currently has a consensus rating of “Buy” and a consensus price target of $8.83.
Several institutional investors and hedge funds have recently bought and sold shares of AMRS. Vivo Capital LLC lifted its holdings in shares of Amyris by 97.2% in the 3rd quarter. Vivo Capital LLC now owns 5,575,118 shares of the biotechnology company’s stock valued at $44,266,000 after buying an additional 2,748,407 shares during the period. BlackRock Inc. lifted its holdings in shares of Amyris by 50.2% in the 4th quarter. BlackRock Inc. now owns 3,419,786 shares of the biotechnology company’s stock valued at $11,421,000 after buying an additional 1,142,354 shares during the period. AWM Investment Company Inc. acquired a new stake in shares of Amyris in the 3rd quarter valued at approximately $5,876,000. WS Management Lllp acquired a new stake in shares of Amyris in the 4th quarter valued at approximately $2,101,000. Finally, Pinnacle Associates Ltd. acquired a new stake in shares of Amyris in the 4th quarter valued at approximately $1,154,000. 36.69% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2019/03/19/amyris-amrs-releases-quarterly-earnings-results.html.
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Read More: What are the reasons investors use put options?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.